These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 31088543)

  • 21. Clinical outcomes in Caucasian patients with polypoidal choroidal vasculopathy.
    Agorogiannis EI; Pearce IA; Yadav S; Parry DG; Beare NAV
    Eye (Lond); 2018 Nov; 32(11):1731-1739. PubMed ID: 30002485
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CHOROIDAL THICKNESS AS A PROGNOSTIC FACTOR OF PHOTODYNAMIC THERAPY WITH AFLIBERCEPT OR RANIBIZUMAB FOR POLYPOIDAL CHOROIDAL VASCULOPATHY.
    Sakurada Y; Sugiyama A; Tanabe N; Kikushima W; Kume A; Iijima H
    Retina; 2017 Oct; 37(10):1866-1872. PubMed ID: 28002268
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Short-term efficacy of intravitreal aflibercept for patients with treatment-naïve polypoidal choroidal vasculopathy.
    Ijiri S; Sugiyama K
    Graefes Arch Clin Exp Ophthalmol; 2015 Mar; 253(3):351-7. PubMed ID: 25023147
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intravitreal Aflibercept and Ranibizumab Injections for Polypoidal Choroidal Vasculopathy.
    Cho HJ; Kim KM; Kim HS; Han JI; Kim CG; Lee TG; Kim JW
    Am J Ophthalmol; 2016 May; 165():1-6. PubMed ID: 26921806
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Photodynamic therapy combined with intravitreal injection of vascular endothelial growth factor antibody for polypoidal choroidal vasculopathy.
    Moon SW; Kim MS; Kim ES; Yu SY; Kwak HW
    Ophthalmologica; 2011; 225(3):169-75. PubMed ID: 21273795
    [TBL] [Abstract][Full Text] [Related]  

  • 26. AFLIBERCEPT FOR POLYPOIDAL CHOROIDAL VASCULOPATHY: As Needed Versus Fixed Interval Dosing.
    Inoue M; Yamane S; Taoka R; Arakawa A; Kadonosono K
    Retina; 2016 Aug; 36(8):1527-34. PubMed ID: 26710307
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Aflibercept therapy for polypoidal choroidal vasculopathy: short-term results of a multicentre study.
    Koizumi H; Kano M; Yamamoto A; Saito M; Maruko I; Sekiryu T; Okada AA; Iida T
    Br J Ophthalmol; 2015 Sep; 99(9):1284-8. PubMed ID: 25777816
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Short-term focal macular electroretinogram of eyes treated by aflibercept & photodynamic therapy for polypoidal choroidal vasculopathy.
    Takayama K; Kaneko H; Kataoka K; Ueno S; Chang-Hua P; Ito Y; Terasaki H
    Graefes Arch Clin Exp Ophthalmol; 2017 Mar; 255(3):449-455. PubMed ID: 27538907
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combined photodynamic therapy with intravitreal bevacizumab injections for polypoidal choroidal vasculopathy: long-term visual outcome.
    Kang HM; Koh HJ; Lee CS; Lee SC
    Am J Ophthalmol; 2014 Mar; 157(3):598-606.e1. PubMed ID: 24269378
    [TBL] [Abstract][Full Text] [Related]  

  • 30. One-year result of aflibercept treatment on age-related macular degeneration and predictive factors for visual outcome.
    Oishi A; Tsujikawa A; Yamashiro K; Ooto S; Tamura H; Nakanishi H; Ueda-Arakawa N; Miyake M; Akagi-Kurashige Y; Hata M; Yoshikawa M; Kuroda Y; Takahashi A; Yoshimura N
    Am J Ophthalmol; 2015 May; 159(5):853-60.e1. PubMed ID: 25634529
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and Safety of Ranibizumab With or Without Verteporfin Photodynamic Therapy for Polypoidal Choroidal Vasculopathy: A Randomized Clinical Trial.
    Koh A; Lai TYY; Takahashi K; Wong TY; Chen LJ; Ruamviboonsuk P; Tan CS; Feller C; Margaron P; Lim TH; Lee WK;
    JAMA Ophthalmol; 2017 Nov; 135(11):1206-1213. PubMed ID: 28983556
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of photodynamic therapy plus intravitreal aflibercept with subtenon triamcinolone injections for aflibercept-resistant polypoidal choroidal vasculopathy.
    Sakai T; Kato N; Kubota M; Tsuneoka H
    Graefes Arch Clin Exp Ophthalmol; 2017 Aug; 255(8):1565-1571. PubMed ID: 28601912
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association of an age-related maculopathy susceptibility 2 gene variant with the 12-month outcomes of intravitreal aflibercept combined with photodynamic therapy for polypoidal choroidal vasculopathy.
    Nakai S; Matsumiya W; Miki A; Honda S; Nakamura M
    Jpn J Ophthalmol; 2019 Sep; 63(5):389-395. PubMed ID: 31376050
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Two-year results of photodynamic therapy combined with intravitreal anti-vascular endothelial growth factor for polypoidal choroidal vasculopathy.
    Kim M; Kim K; Kim DG; Yu SY; Kwak HW
    Ophthalmologica; 2011; 226(4):205-13. PubMed ID: 21893965
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Photodynamic therapy for polypoidal choroidal vasculopathy.
    Nowak-Sliwinska P; van den Bergh H; Sickenberg M; Koh AH
    Prog Retin Eye Res; 2013 Nov; 37():182-99. PubMed ID: 24140257
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Real world experience of the treatment outcome between photodynamic therapy combined with ranibizumab and aflibercept monotherapy in polypoidal choroidal vasculopathy.
    Ma IH; Hsia Y; Hsieh YT; Ho TC; Lai TT; Yang CM; Yang CH
    Sci Rep; 2021 Oct; 11(1):20115. PubMed ID: 34635762
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ONE-YEAR RESULTS OF INTRAVITREAL AFLIBERCEPT FOR POLYPOIDAL CHOROIDAL VASCULOPATHY.
    Hara C; Sawa M; Sayanagi K; Nishida K
    Retina; 2016 Jan; 36(1):37-45. PubMed ID: 26383709
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of Time to Retreatment and Visual Function Between Ranibizumab and Aflibercept in Age-Related Macular Degeneration.
    Inoue M; Yamane S; Sato S; Sakamaki K; Arakawa A; Kadonosono K
    Am J Ophthalmol; 2016 Sep; 169():95-103. PubMed ID: 27320059
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of fixed-dosing aflibercept for treating polypoidal choroidal vasculopathy: 1-year results of the VAULT study.
    Lee JE; Shin JP; Kim HW; Chang W; Kim YC; Lee SJ; Chung IY; Lee JE;
    Graefes Arch Clin Exp Ophthalmol; 2017 Mar; 255(3):493-502. PubMed ID: 27628062
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Benefits of aflibercept treatment for age-related macular degeneration patients with good best-corrected visual acuity at baseline.
    Minami S; Nagai N; Suzuki M; Kurihara T; Sonobe H; Kamoshita M; Uchida A; Shinoda H; Takagi H; Sonoda S; Sakamoto T; Tsubota K; Ozawa Y
    Sci Rep; 2018 Jan; 8(1):58. PubMed ID: 29311612
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.